Decades of being overshadowed by the booming dietary supplement industry have not deterred renewed legislative and regulatory interest in botanical drugs. In a significant development on Capitol Hill, Congresswoman Lauren Boebert (R-CO) introduced the Advancing Botanical Drug Development Act in late August. This proposed legislation seeks to bolster intellectual property (IP) protections for a category of product development that has languished since its establishment by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) in 2006. While botanical drugs, like supplements, are derived from plant materials, their critical distinction lies in their intended use: they are expressly developed to diagnose, treat, and prevent diseases in humans, a purpose that necessitates rigorous scientific validation and regulatory oversight far beyond that required for dietary supplements.
The Advancing Botanical Drug Development Act proposes to grant a 12-year market exclusivity period to developers of botanical drugs. This incentive is designed to stimulate much-needed research and investment in a sector that has shown minimal traction compared to the explosive growth and innovation witnessed in the dietary supplement market over the past two decades. Crucially, lawmakers are emphasizing that this initiative will not compromise the stringent clinical standards required for botanical drug approval. "Botanical drugs are FDA-approved medicines, not dietary supplements," stated Representative Boebert in a press release accompanying the bill’s introduction. This distinction is paramount, as it underscores the fundamental difference in regulatory pathways and the therapeutic intent of these plant-derived medicinal products.
The legislative push has been met with complementary actions from the FDA, signaling a broader governmental interest in this underdeveloped sector. Just a week after Representative Boebert’s announcement, the FDA opened a public docket to gather input and assess the current landscape of botanical drug development. This comment period, extending through November 3, 2026, follows a series of proactive engagements by the FDA, including a roundtable discussion hosted by its Reagan-Udall Foundation. Further international collaboration is on the horizon, with a joint workshop scheduled with the European Medicines Agency (EMA) for September 25, 2026. This collaborative effort aims to share insights and learn from the regulatory challenges and successes experienced in the European Union concerning botanical medicines.
Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health at CDER, highlighted the potential of botanical drug development in a statement: "Given that many people use botanicals for self-treatment, botanical drug products represent an area where greater scientific development could create new opportunities for patients." This sentiment underscores the therapeutic promise inherent in plant-derived compounds and the need for robust scientific inquiry to unlock their full potential for patient benefit.
A Sparse Market: The Four Botanical Drugs Approved in the U.S.
The journey for botanical drugs in the United States has been notably arduous, with only four such products successfully navigating the FDA’s rigorous New Drug Application (NDA) and Biologics License Application (BLA) pathways. These pioneering medications, all approved over a decade ago, include Veregen, a topical treatment for genital warts utilizing sinecatechins derived from green tea. Mytesi and Fulyzaq, both developed for non-infectious diarrhea in HIV patients, feature crofelemer, a compound extracted from the dragon’s blood tree. NexoBrid, a biologic derived from pineapple stems, is used for the debridement of dead tissue in burn patients. The fourth approved drug, Filzuvez, contains birch bark extracts and is indicated for the treatment of wounds associated with epidermolysis bullosa.
These limited approvals stand in stark contrast to the vibrant market for dietary supplements. The regulatory hurdles and substantial investment required for drug development have historically deterred many from pursuing botanical drug pathways. For context, the European Medicines Agency (EMA) approved Qutenza, a topical capsaicin treatment for neuropathic pain, in 2009. While some common botanicals like psyllium and witch hazel have received Over-the-Counter (OTC) approval based on well-established safety monographs, these do not undergo the same level of clinical scrutiny as prescription botanical drugs.
Roy Upton, founder, president, and editor of the American Herbal Pharmacopoeia (AHP), expressed a critical perspective on the current state of botanical drug approvals. "Considering there are only four approved botanical drugs over 20 years of the category’s existence, I wouldn’t call that a lot of interest," Upton remarked. He further elaborated, "None of these are really botanicals. These are botanical isolates approved for uncommon indications." This critique points to a potential disconnect between the public perception of botanicals and the highly purified, specific compounds that have met the stringent criteria for drug approval. The challenge lies in translating the broad therapeutic potential of whole plant materials into precisely defined, scientifically validated medicinal products.
Lessons from the European Landscape: A Stagnant Parallel?
The United States is not alone in its struggles to foster a robust botanical drug market. While the United Kingdom offers a specific marketing authorization for plant-derived drugs, this pathway is rarely utilized within the broader European Union. The high clinical requirements and associated costs present significant barriers to entry, even with existing IP protections. Similar to the U.S., the botanical drug category in the EU is largely overshadowed by the more popular and accessible food supplement and Traditional Herbal Registration (THR) regulatory schemes.
Dr. Joerg Gruenwald, founder and chief scientific advisor of the research and consulting company Analyze & Realize GmbH, observed the parallels between the two continents. "The supplement category is growing faster in Europe, with lots of new products and innovations," Dr. Gruenwald stated. "In comparison, herbal drugs are much more stagnant." This observation suggests that the underlying challenges—high development costs, lengthy approval processes, and limited market incentives—are consistent across major regulatory jurisdictions.
Gruenwald, however, expressed support for initiatives aimed at improving the regulatory framework for herbal drugs. "I support all initiatives that try to develop better regulations for herbal drugs," he said. "The drug pathway has tough requirements, high investment costs, and a long process for registration. Whether in the US or EU, it will take a lot of money and government support to open an important avenue like this." His comments underscore the critical need for substantial financial investment and governmental backing to revitalize this therapeutic avenue. The proposed 12-year market exclusivity in the U.S. bill is a direct response to this identified need for enhanced incentives.
Asymmetric Politics and the Blurring Lines Between Supplements and Drugs
The renewed focus on botanical drugs is occurring against a backdrop of significant regulatory attention being paid to the dietary supplement industry. As supplement stakeholders advocate for modernizing regulations—including mandatory product registration, expanded access to Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs), federal uniformity, and streamlined self-affirmed Generally Recognized As Safe (GRAS) processes—botanicals are now finding themselves at the nexus of policy discussions for both drugs and supplements.
This confluence of regulatory attention creates a complex environment where ingredients can potentially serve both supplement and drug applications, leading to a blurring of established categories. The "modernization" umbrella now seems to encompass potential reforms for both dietary supplements and pharmaceutical products derived from botanicals. During the Trump Administration, Acting FDA Commissioner Kyle Diamantas issued a statement emphasizing a commitment to modernizing regulatory frameworks. "Under the Trump Administration, we are committed to modernizing regulatory frameworks to ensure promising, natural health options are evaluated through rigorous science," Diamantas stated. He further elaborated, "Botanical drug products represent a critical area where greater scientific development can unlock new therapeutic opportunities for American patients while maintaining the highest safety standards."
This dual focus suggests a potential shift in how natural compounds are perceived and regulated. However, regardless of whether they are pursued as drugs or supplements, botanical products will continue to confront inherent formulation challenges. The inherent variability of live plant material, leading to batch-to-batch inconsistencies in quality, and the complexities of developing multi-ingredient clinical trials remain significant obstacles. The increased scrutiny from both legislative bodies like Congresswoman Boebert’s office and regulatory agencies like the FDA could, however, spur innovation across both the supplement and drug domains of botanical products.
The Unfolding Trend of Medicalization in Health and Wellness
The emerging interest in botanical drugs can be seen as a manifestation of a broader trend towards the "medicalization" of the health and wellness sector, a phenomenon also evident in the growing prominence of peptides and intravenous (IV) therapies within the supplement space. This trend directly challenges the fundamental definition of dietary supplements and their regulatory boundaries. The core question at play is whether these products are intended as food ingredients designed to complement the diet with synergistic benefits, or if they are highly potent isolates engineered to exert drug-like impacts on human health.
Leading industry trade associations have been vocal in their calls for a more expansive definition of "dietary supplement," moving beyond the traditional food-use requirements currently dictated by the FDA. However, the ultimate outcome of these advocacy efforts remains uncertain. What is becoming increasingly clear is the further erosion of the clear distinctions between supplements and drugs, particularly if the U.S. government actively supports the development of botanicals under either regulatory framework.
Roy Upton of the American Herbal Pharmacopoeia articulates this definitional challenge: "Unfortunately, in the US, there does not appear to be a threshold where a supplement crosses over into the drug world." He contrasts this with international perspectives: "Internationally, a traditional medicine is defined predominantly as a Galenic preparation, and relatively pure compounds are restricted to conventional drug categories. I don’t know if this is an emerging trend, but it is a foundational, definitional problem within DSHEA [Dietary Supplement Health and Education Act]." This highlights a fundamental ambiguity in current U.S. legislation that may need to be addressed as the scientific and commercial landscape of botanical products evolves. The Advancing Botanical Drug Development Act represents a significant step in attempting to clarify and invigorate one specific, yet crucial, facet of this complex and evolving field.
